CLXT - Cellectis: FYE 2021 TALEN CAR-T Data Announcement Should Catalyse Strong Upside

• Cellectis S.A. is an early clinical-stage immuno-oncology biotechnology company specializing in gene-edited T-cells that express chimeric antigen receptors for treating cancer.
• Cellectis offers a specialization in gene-editing, enabling their CAR-T product candidates to have additional safety and efficacy attributes alongside healthy tissue-protective measures, enabling high tolerance oncology therapeutics.
• Cellectis' pipeline has 7 internal candidates and 5 external candidates with internal clinical-stage indications covering acute lymphoblastic leukemia (UCART22: Phase 1), acute myeloid leukemia (UCART123: Phase 1), and multiple myeloma (UCARTCS1: Phase 1).
• Cellectis is not in the greatest financial position with cash of $211M (March 2021) pulled down by -$169M in TTM cash burn, equating to about 1.25 years of operational funding, but in April 2021 Cellectis ran their +$45.5M ATM offering, while the company states it should fund operations into early 2023.
• In summary, the author projects Cellectis S.A. as a "buy" at a 3-4 year price target of $70 (+382% upside).

For further details see: